For most subgroups, the ICER for the ADCHM group as compared to the PLCHM group was below the WTP threshold of $37,653/QALY, ranging from $21,697/QALY in patients who never smoked (probability of cost-effectiveness, 93.7%) to $33099/QALY for PD-L1 tumor proportion score ≥1% (probability of cost-effectiveness, 63.1%). This evidence concerns the gene CD274 and neoplasm.